Skip to content
AlternativeMed

SPECIALTY TOPICS · GUIDE

BPC-157: What Research Shows and What It Does Not

BPC-157 is an unapproved research peptide promoted for injury recovery. What animal and human studies show, what regulators and sport bodies say, and what remains unknown.

Content last updated . This page has not been medically reviewed.

Back to Peptides & Modern Research
Quick answer
BPC-157 is a research peptide, not an approved medicine in any jurisdiction checked here. Almost all of the supporting research is in rodents. The few human reports are tiny, mostly uncontrolled, and rated very low certainty. [1] This page is education only. It gives no amounts, no sourcing and no how-to-use details.

Evidence labels used on this page: preclinical (cells or animals only), insufficient evidence, marketing claim and evidence of harm (used only where a regulator or study reports a harm). "Preclinical" means the finding comes from cells or animals and has not been shown in people.

What it is and how it is named

BPC-157 ("body protection compound 157") is a synthetic pentadecapeptide, meaning a chain of 15 amino acids. FDA's review describes it as a fragment of a protein originally isolated from human gastric juice. [2] Records and products may refer to the "free base" or to an "acetate" salt form,; FDA evaluates the two forms separately. [2] A brand name, a research label and a pharmacy-prepared product are not interchangeable with the molecule studied in a paper, and the contents of products sold online are unverified. [3]

What research shows

Animals and laboratory work (preclinical). A 2019 review described consistently positive tendon, ligament and muscle healing in animal models but noted most work was in small rodent studies from a handful of research groups, with efficacy "yet to be confirmed in humans." [9] A 2025 systematic review found 36 studies, 35 preclinical and one clinical. [10] A 2026 critical review of rodent ischemia-reperfusion studies found protective changes but called the evidence heterogeneous, often with short observation periods and single-dose designs. [11] A 2026 review of drug-development barriers noted a very short plasma half-life in animals that does not obviously match effects lasting hours to days, and no validated pharmaceutical formulation. [12] PubMed also indexes at least one withdrawn (retracted) BPC-157 rat paper from 2025, a reminder to check individual papers. [13]

People. A 2026 systematic review found three human studies with 30 participants in total: a retrospective knee-injection report, a retrospective bladder study and a small intravenous safety pilot. All were judged poor quality, with very low certainty. The authors said it should not be used clinically outside approved, high-quality trials. [1] The knee report was a one-clinic chart review with phone follow-up of 16 patients and no validated function tools. [14] FDA's own search found five clinical studies using BPC-157 and no human pharmacokinetic data after oral, subcutaneous, nasal or transdermal use. [2]

Registered trials. ClinicalTrials.gov lists a phase 2 trial of BPC-157 for acute hamstring strain (120 planned, recruiting, started February 2026) [15] and a small phase 1 safety and pharmacokinetics trial in healthy volunteers (42 planned, status unknown, last update 2015). [16] Registered is not the same as completed or published, and no results from either were found.

Label for human efficacy in any injury or condition: insufficient evidence. Label for the "healing" claims on sale sites: marketing claim.

Related guides

How to evaluate peptide claims, tendon and ligament injury claims, what the regulatory categories mean and talking with a health professional.

Frequently asked questions

Is BPC-157 an approved medicine?

Not in any jurisdiction checked here. FDA's compounding review found it is not a component of an approved drug and proposed against listing it, and Health Canada lists it among unauthorized peptides. [2][3]

Does BPC-157 heal tendons in people?

Proper evidence not found. Animal studies are positive, but human data are three small, poor-quality studies. [1]

Is BPC-157 allowed in sport?

No. WADA's 2026 Prohibited List names it as prohibited at all times. [8]

Did FDA recently decide on BPC-157?

FDA's committee met in July 2026 and FDA proposed not listing it, but the final decision was not found on the pages read. [6][7]

Are online BPC-157 products reliable?

Not verifiably. Health Canada says unauthorized peptide products may contain the wrong amount or contaminants. [3]

More details: evidence, limits and cautions

The details behind this page: cautions, limits of the evidence and where sources disagree. Open any note to read it.

Regulatory and sport status (as read on 2026-10-22)
Laws and agency positions change, and this is not legal advice.
  • United States, FDA, compounding lists. FDA's page on bulk substances that may present significant safety risks (content current as of 04/22/2026) lists BPC-157 in its table of substances that were nominated and then withdrawn by the nominators. For it FDA reports immunogenicity risk for certain routes and says it found no, or only limited, safety information for the proposed routes. [4] Compounded drugs are not FDA-approved. [5]
  • United States, advisory committee. FDA's Pharmacy Compounding Advisory Committee met on July 23 and 24, 2026 to discuss BPC-157 for the 503A bulks list; the use FDA evaluated was ulcerative colitis. [6] FDA's own briefing document proposed that BPC-157 not be included. It cited poor physical and chemical characterization, no adequate safety information, and insufficient evidence of effectiveness for ulcerative colitis, a disease with approved treatments. [2] FDA said it would issue no final determination until the committee process and reviews were finished. [7] The committee's vote is not stated on the FDA pages read, so the outcome is not verified here, and no final FDA decision was found.
  • Canada, Health Canada. A public advisory (last updated 2026-04-09) lists BPC-157 among examples of seized unauthorized injectable peptide drugs and says unauthorized drug products are illegal in Canada and have not been assessed for safety, efficacy and quality. [3]
  • Sport, WADA. The 2026 Prohibited List names BPC-157 under non-approved substances, prohibited at all times. [8] See anti-doping rules for peptides.
  • EU, UK, Australia: not verified from an official page this session.
Safety and unknowns
Reports of no adverse effects in tiny studies cannot establish safety. [1] FDA found insufficient clinical safety information to characterize BPC-157's safety profile. [2] Health Canada warns that unauthorized injectable peptides can contain too much, too little or none of the stated ingredient, or contaminants. [3] No data exist for pregnancy, breastfeeding, children, older adults or people with heart, liver, kidney or cancer histories; proper evidence not found for these groups in the sources read. See peptide safety and adverse events.
References
  1. Poolton et al. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthop Belg 2026. PubMed. Read 2026-10-22.
  2. U.S. Food and Drug Administration. FDA Briefing Document: BPC-157-related bulk drug substances, Pharmacy Compounding Advisory Committee, July 23-24, 2026. Read 2026-10-22.
  3. Health Canada. Think twice before injecting peptides bought online: unauthorized products can seriously harm you (public advisory, last updated 2026-04-09). Read 2026-10-22.
  4. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 04/22/2026). Read 2026-10-22.
  5. U.S. Food and Drug Administration. Compounding and FDA: Questions and Answers. Read 2026-10-22.
  6. U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (content current as of 08/06/2026). Read 2026-10-22.
  7. U.S. Food and Drug Administration. FDA Briefing Document, Pharmacy Compounding Advisory Committee, July 23-24, 2026 (overview and points for the committee). Read 2026-10-22.
  8. World Anti-Doping Agency. 2026 Prohibited List (in force 1 January 2026; the page says each new list is published in October, and the 2027 list was not read). Read 2026-10-22.
  9. Gwyer D et al. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res 2019. PubMed. Read 2026-10-22.
  10. Vasireddi N et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J 2025. PubMed. Read 2026-10-22.
  11. Demirtas H. BPC 157 in rodent ischemia-reperfusion injury: a critical review of preclinical evidence. Int J Mol Sci 2026. PubMed. Read 2026-10-22.
  12. Mateescu DM et al. BPC-157 as an investigational peptide therapeutic: biopharmaceutical challenges, formulation strategies, and translational development barriers. Pharmaceutics 2026. PubMed. Read 2026-10-22.
  13. Withdrawn: Stable gastric pentadecapeptide BPC 157 as a therapy of severe electrolyte disturbances in rats. Curr Neuropharmacol 2025 (indexed in PubMed as a retracted publication). Read 2026-10-22.
  14. Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med 2021. PubMed. Read 2026-10-22.
  15. ClinicalTrials.gov. NCT07437547 Phase 2 BPC-157 for acute hamstring strain; Hudson Biotech. Read 2026-10-22.
  16. ClinicalTrials.gov. NCT02637284 PCO-02 safety and pharmacokinetics trial of BPC-157 (Bepecin); PharmaCotherapia. Read 2026-10-22.
Education, not medical advice. This page is for general information. It does not diagnose or treat any condition and is not a substitute for care from a qualified health professional. Natural does not automatically mean safe. Ask a clinician or pharmacist before changing your care, especially if you take medication, are pregnant or breastfeeding, or have a health condition.